Laurus Labs Limited’s IPO to open on December 06, 2016 with Price Band of 426 – 428 per Equity Share each of Face Value of 10 each
· The Floor Price is 42.6 times of the Face Value and the Cap Price is 42.8 times of the Face Value.
· Bid can be made for a minimum of 35 Equity Shares and in multiples of 35 Equity Shares thereafter
· Discount to Eligible Employees 40 to the Offer Price
· Offer for Sale of 24,107,440 equity shares by selling shareholders
· Fresh issue of equity share aggregating up to Rs. 3,000 million
· Bid/Offer Opening Date – December 06, 2016 and Bid/Offer Closing Date – December 08, 2016
Hyderabad, December 2, 2016:Hyderabad based Laurus Labs Limited, a research and development driven pharmaceutical company (the “Company”) will launch its Initial Public Offering (“IPO” or the “Offer”) which is scheduled to open on December 06, 2016 and close on December 08, 2016, with a price band of INR426– INR428 per equity shares of face value of Rs. 10 each of the Company (the “Equity Shares”). The Company may, in consultation with the Book Running Lead Managers (the “BRLMs”), consider participation by Anchor Investors in accordance with the Securities and Exchange Board of India (Issue of Capital and disclosure Requirements) Regulations, 2009 (“SEBI ICDR Regulations”). The Anchor Investors shall Bid during the Anchor Investor Bid/Offer Period, i.e., one Working Day prior to the Bid/Offer Opening Date.
Dr.Satyanaraya Chava, the CEO of Laurus Labs at the IPO Press Conference
Dr.Satyanaraya Chava, the CEO of Laurus Labs at the IPO Press Conference
Dr.Satyanarayana Chava, CEO and Mr. V.V.RaviKumar ED & CFO of Laurus Labs at the Press Conference
The Offer consists of fresh issue of Equity Shares aggregating up to Rs. 3,000 million (“Fresh Issue”) and an offer for sale of 24,107,440 Equity Shares (“Offer for Sale”) by the selling shareholders namely Aptuit (Asia) Private Limited, Bluewater Investment Ltd, FIL Capital Management (Mauritius) Limited and Fidelity India Principals (acting through its trustee FIL Capital Advisors) (the “Selling Shareholders”).The Offer includes a reservation of up to such number of Equity Shares aggregating up to Rs. 125 million, for subscription by eligible employees (as defined in the RHP) not exceeding 5% of the Company’sPost-Offer paid up Equity Share capital (the “Employee Reservation Portion”). The Offer less the Employee Reservation Portion is hereinafter referred to as the “NetOffer”.
The Company will not receive any proceeds from the Offer for Sale and all proceeds from the Offer for Sale will go to the Selling Shareholders. The Company proposes to use the net proceeds from the Fresh Issue towards pre-payment of term loans and general corporate purposes.
The Offer is being made through the Book Building Process,in terms of of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”), andin accordance with Regulation 26(1) of the SEBI ICDR Regulations, wherein 50% of the Net Offer shall be allocated on a proportionate basis to Qualified Institutional Buyers (“QIBs”),provided thatour Company may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors (“Anchor Investor Portion”) at the Anchor Investor Allocation Price, on a discretionary basis, out of which at least one-third shall be reserved for domestic Mutual Funds only, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Offer Price, in accordance with the SEBI ICDR Regulations.
5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price.
Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price such that, subject to availability of Equity Shares, each Retail Individual Bidder shall be Allotted not less than the minimum Bid Lot, and the remaining Equity Shares, if available, shall be Allotted to all Retail Individual Bidders on a proportionate basis. Further, such number of equity shares aggregating up to Rs.125 million shall be available for allocation on a proportionate basis to Eligible Employees, subject to Valid Bids being received from them at or above the offer price after the Employee Discount. All potential investors, other than Anchor Investors, are required to mandatorily utilise the Applications Supported by Blocked Amount (“ASBA”) process by providing the details of their respective bank accounts in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks (“SCSBs”) to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see the section titled “Offer Procedure” on page 530 of the RHP.
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Jefferies India Private Limited and SBI Capital Markets Limited are the BRLMs to the Offer. The Registrar to the Offer is Karvy Computershare Private Limited.
The Equity Shares of the Company are proposed to be listed on the BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”)
About Laurus Labs Limited:
Laurus Labs Limited (“Laurus Labs”) is a leading research and development (“R&D”) driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (“APIs”) for select, high-growth therapeutic areas of anti-retrovirals (“ARVs”) and Hepatitis C. Laurus Labs also manufactures APIs in oncology and other therapeutic areas. Their strategic and early investments in R&D and manufacturing infrastructure have enabled them to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing “donor-funded access-to-medicines markets” of Sub-Saharan Africa, South-East Asia and Latin America. During the financial year 2016, Laurus Labs sold APIs in 32 countries. Laurus Labs also has a growing synthesis and nutraceutical/cosmeceutical ingredients businesses. Further, they are increasingly focused towards growing their integrated generics finished dosage forms (“FDFs”) business in which they have made significant investments over the last two financial years. Laurus Labs operates in four business lines: Generics – APIs, Generics – FDFs, Synthesis and Ingredients.
All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP dated November 25, 2016